Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cretan IAMA
- Development stage
- Unknown
- Lead developer
- Olvos Science
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Cretan IAMA is a botanical combination product consisting of essential oil extracts from three Mediterranean aromatic plants: *Coridothymus capitatus* (Spanish oregano/thyme), *Origanum dictamnus* (Cretan dittany), and *Salvia fruticosa* (Greek sage), dissolved in extra-virgin olive oil. Developed by Olvos Science SA (a subsidiary of Galenica), it is indicated for the management of upper respiratory tract infections (URTI), including those caused by influenza A (H1N1), influenza B, and human rhinovirus. The drug's mechanism of action involves interfering with the trafficking of the influenza A Nucleoprotein (NP) and reducing systemic inflammatory markers such as C-reactive protein (CRP). Clinical studies have demonstrated its efficacy in reducing the duration and severity of URTI symptoms and decreasing systemic inflammation.
- Brand names
- Cretan IAMA
- Other names
- Coridothymus capitatus extract + Origanum dictamnus extract + Salvia fruticosa extractCretan Aromatic Plant essential oilcoridothymus capitatus extract + origanum dictamnus extract + salvia fruticosa/promifera extract
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)Viral lipid envelope
Beyond the preview
Go deeper on Cretan IAMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cretan IAMA.